Results 171 to 180 of about 166,653 (343)

AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Inhaled corticosteroids (ICS) plus bronchodilator are recommended for the treatment of asthma. Targeting the JAK1‐dependent pathway may be an alternative for asthma management in patients with incomplete response to ICS. The aim of this study was to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD0449, a
Anna Lundahl   +11 more
wiley   +1 more source

Citrus Flavonoids for Cystic Fibrosis Treatment

open access: yesChemBioChem, EarlyView.
Studies conducted since the late 1990s show substantial activity of selected citrus flavonoids as cystic fibrosis transmembrane conductance regulator (CFTR) membrane protein activators. The thesis of this work is that aptly formulated citrus flavonoids hold sigificant potential for developing a multitarget treatment of cystic fibrosis combining in a ...
Mario Pagliaro   +5 more
wiley   +1 more source

Airways obstruction associated with graft versus host disease after bone marrow transplantation. [PDF]

open access: bronze, 1984
S. E. Wyatt   +9 more
openalex   +1 more source

Synthesis and Evaluation of Fluorinated Peptidomimetics Enabling the Development of 18F‐Labeled Radioligands Targeting Muscarinic Acetylcholine Receptor Subtype M3

open access: yesChemMedChem, EarlyView.
Fluorinated peptidomimetics targeting muscarinic acetylcholine receptor subtype M3: Fluorinated peptidomimetic compounds based on a β‐alanine‐glycine scaffold, with lead compound 24 demonstrating high M3 selectivity and submicromolar potency. The first M3‐selective positron emission tomography radioligand, [18F]24, is synthesized and will be evaluated ...
Miguel A. Herrera‐Rueda   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy